Abstract
Aim
To compare 6 months of treatment with bimatoprost and timolol in terms of their hypotensive efficacy and secondary effects, including changes in macular thickness and the inflammatory reaction induced in the anterior chamber.
Methods
A prospective, randomized, parallel-group trial performed on 30 eyes of 30 patients per group. The main outcome measure was the difference between the IOP value taken between the baseline visit and the 6-month-visit. Macular thickness determined through optical coherence tomography and anterior chamber inflammation estimated using the laser flare meter was also evaluated. Adverse events were recorded during the study period.
Results
Bimatoprost treatment gave rise to a significantly lower mean IOP than timolol in all follow-up visits as from the first month (P<0.05). Bimatoprost achieved high percentage IOP reductions from baseline in a significantly higher proportion of patients (P<0.05). Macular thickness and anterior chamber flare failed to vary significantly both between the two groups and within each group during the 6-month evaluation (P>0.05).
Conclusions
Bimatoprost 0.03% once daily showed a greater efficacy then timolol 0.05% twice daily in patients with elevated IOP. No significant differences were detected in macular thickness or anterior uveitis using optical coherence tomography and laser flare photometry.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Parentin F . Granulomatous anterior uveitis associated with bimatoprost. A case report. Ocul Immunol Inflam 2003; 11: 67–71.
Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC . Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999; 77: 668–672.
Kroll DM, Schuman JS . Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment of glaucoma. Am J Ophthalmol 2003; 133: 401–403.
Wand M, Gaudio AR . Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol 2002; 133: 403–405.
Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K et al; Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120: 1286–1293.
Cohen JS, Gross RL, Cheetham JK, Vanderburgh AM, Berstein P, Whitcup SM . Two year double masked comparison of Bimatoprost with Timolol in glaucoma and ocular hypertension. Surv Ophthalmol 2004; 49: S45–S52.
Furuichi M, Chiba T, Abe K, Kogure S, Iijima H, Tsukahara S et al. Cystoid macular edema associated with the use of latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma 2001; 10: 233–236.
Miyake K, Ota I, Ibaraki N, Akura J, Ichihashi S, Shibuya Y et al. Enhanced disruption of the blood aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol 2001; 119: 387–394.
Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S . Latanoprost accelerates disruption of the blood aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakia. Arch Ophthalmol 1999; 117: 34–40.
Furuichi M, Chiba T, Abe K, Kogure S, Iijima H, Tsukahara S et al. Cystoid macular edema associated with the use of Latanoprost. J Am Optom Asocc 1998; 69: 122–128.
Lima MC, Paranhos Jr A, Salim S, Honkanen R, Devgan L, Wand M et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma 2000; 9: 317–321.
Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC . Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999; 77: 668–672.
Linden C, Nuija E, Alm A . Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997; 81: 370–372.
Linden C, Alm A . The effect on IOP of latanoprost once or four times daily. Br J Ophthalmol 2001; 85: 1163–1166.
Acknowledgements
This study was partly financed by the Instituto de Salud Carlos III, ‘Project C03/13: Clinical and basic research for the prevention of blindness’. The authors declare they have no commercial interests in any product, equipment or procedure mentioned in this article and that it has not been published elsewhere or submitted to another journal.
Author information
Authors and Affiliations
Corresponding author
Additional information
Section: Original clinical research article
Rights and permissions
About this article
Cite this article
Martin, E., Martinez-de-la-Casa, J., Garcia-Feijoo, J. et al. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. Eye 21, 164–168 (2007). https://doi.org/10.1038/sj.eye.6702149
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702149
Keywords
This article is cited by
-
Long-term reduction of laser flare values after trabeculectomy but not after cyclodestructive procedures in uveitis patients
International Ophthalmology (2011)
